| Bioactivity | Befotertinib (D-0316) mesylate is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib (D-0316) mesylate can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC)[1]. |
| Name | Befotertinib mesylate |
| CAS | 2226167-02-6 |
| Formula | C30H36F3N7O5S |
| Molar Mass | 663.71 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Nagasaka M, et, al. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. J Thorac Oncol. 2021 May;16(5):740-763. |
Befotertinib mesylate
CAS: 2226167-02-6 F: C30H36F3N7O5S W: 663.71
Befotertinib (D-0316) mesylate is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib (D-0316) mesylate ca
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.